ROS1 and non-small cell lung carcinoma: The recommended dosage for adults with ROS1 fusion-positive NSCLC or NTRK fusion-positive solid tumors is 600 mg once daily orally and was determined using a maximum tolerated dose (MTD) approach from the dose escalation study STARTRK-01 [4–6].